Research

15 Celiac Disease Facts Everyone Should Know

stock-photo-3443895-depression-and-sorrow1-216x300[1]

Celiac disease awareness is growing, but misinformation still abounds. Here are 15 celiac disease facts every doctor, patient and member of the public should know.

1. 1 in 700 –

    The average prevalence of celiac disease in the United States 1950. (Mayo)

2. 1 in 100 –

    The average worldwide prevalence of celiac disease across all races today. (NIH) The average prevalence of celiac disease in the United States today. (Mayo)

3. $8,500 – The average annual estimated healthcare cost of each person with untreated celiac disease in the United States. (Cigna/Columbia Celiac Disease Center study) Read More »

Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study

 

PRESS RELEASE
Milestone Marks the First Time a European Patient with Active Celiac Disease has Enrolled in a Clinical Trial for an Investigational Medication from Alba Therapeutics
Last update: 8:22 p.m. EST Nov. 11, 2008
BALTIMORE, Nov 11, 2008 /PRNewswire via COMTEX/ —

Alba Therapeutics Corporation announced today that for the first time, a European patient with active celiac disease has been enrolled in its clinical trial to investigate a treatment for the disease. Alba has enrolled and randomized the newly diagnosed patient from Spain in an eight-week Phase IIb trial with oral larazotide acetate, a tight junction regulator, for the treatment of patients with active celiac disease (CD). The global multi-center, randomized, double-blind, placebo-controlled study will evaluate the clinical and histological efficacy, safety and tolerability of larazotide acetate in 106 active CD subjects adhering to a gluten-free diet, while assessing improvement in the clinical signs and symptoms of celiac disease.

“These are decisive times for our desire to one day be able to offer our celiac patients a treatment that allows them to live more normal lives,” said Dr. Gemma Castillejo, MD, a pediatric gastroenterologist and principal investigator in the study. Dr. Castillejo, a leading European celiac expert from the Sant Joan de Reus University Hospital in Reus, Spain added, “I believe this clinical trial has the potential to be a turning point in the search for treatments for celiac disease.”
“This is a major milestone for the celiac community in Europe,” stated Francisco Leon, MD, PhD, Vice President, Clinical Development and Medical Affairs of Alba. “This is Alba’s sixth human trial with larazotide acetate, and we are excited to be advancing our investigational program for larazotide acetate in this important region of the world.”
About Celiac Disease
Celiac disease is an inherited autoimmune disorder where gluten has been identified as the environmental trigger of the disease. Gluten is an ingested protein found in wheat, barley and rye. Gluten is broken down into gliadin which can pass through the intestinal epithelial barrier during times of increased intestinal permeability. The ingestion of gluten causes an immune response which triggers an inflammatory reaction in the small intestine. This then causes damage to the villi in the small intestine and can lead to total villous atrophy in celiac disease. This results in varying symptoms such as fatigue, skin rash, anemia, fertility issues, joint pain, weight loss, pale sores inside the mouth, tooth discoloration or loss of enamel, depression, chronic diarrhea or constipation, gas and abdominal pain. The immunology and nutritional abnormalities in celiac disease can potentially result in long- term complications such as osteoporosis, refractory sprue, small intestinal cancer, and lymphoma.
Celiac disease is a growing public health concern, affecting approximately 3 million people in the United States and over 6.5 million people worldwide. The only current management of celiac disease is complete elimination of gluten from the diet, which can be very difficult to implement in practice. Additionally, the response to the gluten-free diet is poor in up to 30% of patients, and dietary nonadherence is the chief cause of persistent or recurrent symptoms.(1)
(1) Green, P, and Cellier, C, Review Article,
 Medical Progress, Celiac Disease, N ENGL J MED
 2007;357:1731-43
About “Larazotide Acetate”
Larazotide acetate is an experimental medicine and a tight junction regulator that acts locally by inhibiting the opening of tight junctions in epithelial cells lining the small intestine. In celiac disease, gluten crosses the epithelial barrier and stimulates the immune system, leading to cytokine release, gut inflammation, and opening of tight junctions. This leads to increased paracellular permeability, increased entry of gluten and the establishment of an intestinal permeability-inflammation loop. Larazotide acetate inhibits tight junction opening triggered by both gluten and inflammatory cytokines, thus reducing uptake of gluten. Larazotide acetate disrupts the intestinal permeability-inflammation loop, and reduces symptoms associated with celiac disease. Larazotide acetate is orally formulated, has been granted “Fast Track” designation by the U.S. Food and Drug Administration for the treatment of celiac disease, and is also being evaluated for the treatment of Crohn’s Disease.

For more information about Alba’s clinical trials, please visit the www.clinicaltrials.gov web site and search for Alba Therapeutics.

About Alba
Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies to treat autoimmune and inflammatory diseases and is located in Baltimore, Maryland. Alba’s technology platform is based upon a key pathway that regulates the assembly and disassembly of tight junctions in cell barriers throughout the body. As a result of its unique technology platform, Alba is a leader in mucosal biology and has developed a pipeline of innovative therapeutic candidates that has the potential to modify the course of disease and significantly improve upon existing treatments for a wide range of diseases such as celiac disease, Crohn’s disease, and Asthma/COPD or acute lung injury.
    Media: Mariesa Kemble
    Sam Brown Communications
    608-850-4745
    kemblem@aol.com 

    Corporate: Wendy Perrow, MBA
    Alba Therapeutics Corporation
    410-878-9850
    info@albatherapeutics.com
    http://www.albatherapeutics.com
----------------------
Author Information: John Libonati, Philadelphia, PA
Publisher, Glutenfreeworks.com.
Editor & Publisher, Recognizing Celiac Disease.
John can be reached by e-mail here.

BioLineRx Announces Publication of Pre-clinical Results Demonstrating Efficacy of BL-7010, an Oral Treatment for Celiac Disease and Gluten Sensitivity

Kelly Clayton Gluten Free Works

Just last week BioLineRx, a biopharmaceutical development company announced successful pre-clinical testing of a potentially revolutionary treatment for celiac disease.  This new treatment may help celiac disease patients reduce their gluten toxins to create an overall healthy body for all celiac disease patients.

Jerusalem, Israel – February 21, 2012 – BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced the publication of pre-clinical results demonstrating that BL-7010, an orally available treatment for celiac disease, reduces gluten toxicity (the negative effect of gluten on the patient’s body). The research was published in the February edition of Gastroenterology.

The findings indicate that BL-7010 (previously called P(HEMA-co-SS)) reduces digestion of wheat gluten, thereby decreasing its Read More »

BioLineRX’s BL-7010 Treatment of Celiac Disease and Gluten Sensitivity Presented

biolinerx celiac disease therapy

BioLineRx Therapy BL – 7010 Treats Celiac Disease & Gluten Sensitivity

BioLineRx Ltd, a biopharmaceutical development company, was invited to deliver an oral presentation at the recent 2013 National Education Conference & Gluten-Free Expo, the Celiac Disease Foundation’s annual conference, in Pasadena, California.

Leah Klapper, Ph.D., General Manager, BioLine Innovations Jerusalem, presented BioLineRx’s therapy, BL-7010, for the treatment of celiac, as part of a session entitled Breaking Therapies Beyond the Gluten-Free Diet.

BL-7010 will be presented at Read More »

Boston College Business School Team Seeks Special Dietary Needs Information

A team of business school students from Boston College invites the gluten-free community to participate in an important market research survey. The goal is to learn more about consumers with specific dietary needs. The results of the survey will be used to assist in offering detailed recommendations about how to better support the community with unique, high-quality, gluten-free foods. This survey is intended for market research purposes only. Your opinion will be kept confidential. All results will be reported in the aggregate and not as individual entries. Read More »

Breastfed Babies at Reduced Risk for Developing Celiac Disease Autoimmunity

According to the Centers for Disease Control, as of 2006, 33.1% of women were choosing to exclusively breastfeed their newborn from 0-3 months of age. At the one-year mark, only 22.7% of women were still breastfeeding their baby (non-exclusively).

The American Academy of Pediatrics Committee, the World Health Organization (WHO), the Canadian Pediatric Society, the Pediatric Society of New Zealand, and other similar organizations in various countries worldwide have all made statements on infant feeding and the appropriate time to introduce solid foods into a baby’s diet. The current consensus is that solid food should not be introduced until at least the age of 4-6 months, if not later. Read More »

Celiac Disease 5 Times Higher Than 50 Years Ago – Mayo Clinic Video

Dr. Joseph Murray of the Mayo Clinic explains his landmark study that tested blood samples from 50 years ago and compared them to people of the same ages today. The results: 1. Celiac disease is 5 times more prevalent than it was 50 years ago, 2. People with untreated celiac disease are 4 times more likely to die prematurely than the general population. This breaking information shows us that the rate of celiac disease is rising and people must be identified and diagnosed to insure good health. – John Libonati, Editor. Glutenfreeworks.com

Celiac Disease Study Recruiting Participants

Plaza Research is currently recruiting men and women ages 18 and older who have been diagnosed with Celiac Disease to participate in a paid telephone discussion on the topic of Celiac Disease. The phone interviews are taking place on April 15th and April 27th, 2010 and will last approximately 1 hour in length. All participants will receive $50.00 for their time and opinions.

If you or anyone you know may be interested, please click on the link below to complete the online application for the study. All responses will be reviewed and qualified applications will be called back on first come first served basis until all seats are filled.

LINK TO APPLICATION:

————————
Author Information: Jennifer D. Harris, Atlanta, GA
Jennifer D. Harris, http://www.jenniferglutenfreeingeorgia.blogspot.com/
Gluten-Free Product Specialist, Return to Eden.
Program Chair, Atlanta Metro Celiacs, www.atlantametroceliacs.org
Twitter @jenniferGFinGA

Celiac Expert Answers – Could a Gluten-Free Diet Lead to Other Diseases? Video!

John Libonati Gluten Free Works

Weight loss, fad, miracle cure…there is an enormous amount of misinformation concerning the gluten-free diet in the news, on the internet and even in the medical community.

One of the worst ideas being perpetuated is that following a gluten-free diet can somehow be bad for you.

Dr. Stefano Guandalini, Founder and Medical Director of Columbia University’s Celiac Disease Center, answers the important question – Could following a gluten-free diet lead to other diseases?

Read More »

>